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The innate immune system employs a diverse set of geneti-
cally encoded sensors to detect evidence of infection or cell 
damage in the different compartments of the cell. Cytosolic 
sensors and adaptors in myeloid cells integrate information to 
initiate a strong inflammatory response through the assembly 
of macromolecular protein complexes called inflammasomes. 
Activation of inflammasomes culminates in the activation of 
caspase-1, which enables the maturation and release of pro-
inflammatory cytokines, such as IL-1β and -18, as well as cell 
death by pyroptosis (Vanaja et al., 2015).
The sensor involved determines the specificity of the in-
flammasome and is typically a member of two conserved pro-
tein families: NLRs (nucleotide-binding domain [NBD]– and 
leucine-rich repeat [LRR]–containing proteins), and ALRs 
(AIM2-like receptors). These sensors recruit caspase recruit-
ment domain (CARD)–containing pro–caspase-1 indirectly 
via the interposition of CARD-containing ASC or NLRC4. 
A diverse array of cell damage signals, including potassium ef-
flux, activates NLRP3 inflammasomes through an unknown 
mechanism, which then recruits ASC via interactions be-
tween Pyrin domains (PYDs). AIM2 directly binds to DNA 
with its HIN domain and also engages ASC via PYD–PYD 
interactions. Human NAIP/NLRC4 inflammasomes contain 
two NLRs: NAIP, which senses components of bacterial type 
III secretion systems or flagellin, and NLRC4, which, once 
activated by NAIP, can recruit pro–caspase-1, although ASC 
was required for efficient cytokine secretion in mice (Broz 
et al., 2010b; Yang et al., 2013; Kortmann et al., 2015; Vance, 
2015). Recent cryo-electron microscopy experiments showed 
that a single NAIP family member primes the self-propagated 
incorporation of 9–11 NLRC4 monomers into a wheel-like 
structure (Hu et al., 2015; Zhang et al., 2015).
Local polymerization of PYD and CARD domains, 
both members of the death domain family, determines ac-
tivation thresholds and amplifies the signal (Cai et al., 2014; 
Lu et al., 2014; Sborgi et al., 2015). In their active conforma-
tion, the PYD of NLRP3 and AIM2 nucleate the formation 
of ASCPYD filaments, whereas locally concentrated ASCCARD 
induces the polymerization of pro–caspase-1 CARD. These 
structures have thus far been shown only in vitro, or in cells 
that overexpress single domains of ASC fused to fluorescent 
proteins. Their presence therefore demands verification at 
physiological protein levels in the relevant cell type (Lecht-
enberg et al., 2014). Local concentration of pro–caspase-1 
autocatalytically activates caspase-1, which in turn catalyzes 
the conversion of pro-cytokines into mature IL-1β and -18.
Myeloid cells assemble inflammasomes in response to infection or cell damage; cytosolic sensors activate pro–caspase-1, in-
directly for the most part, via the adaptors ASC and NLRC4. This leads to secretion of proinflammatory cytokines and pyro-
ptosis. To explore complex formation under physiological conditions, we generated an alpaca single domain antibody, VHHASC, 
which specifically recognizes the CARD of human ASC via its type II interface. VHHASC not only impairs ASCCARD interactions in 
vitro, but also inhibits inflammasome activation in response to NLRP3, AIM2, and NAIP triggers when expressed in living cells, 
highlighting a role of ASC in all three types of inflammasomes. VHHASC leaves the Pyrin domain of ASC functional and stabilizes 
a filamentous intermediate of inflammasome activation. Incorporation of VHHASC-EGFP into these structures allowed the vi-
sualization of endogenous ASCPYD filaments for the first time. These data revealed that cross-linking of ASCPYD filaments via 
ASCCARD mediates the assembly of ASC foci.
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Although we understand some of the molecular triggers 
and consequences of inflammasome activation, the under-
lying cell biology and the molecular interactions involved 
require further study. Reconstitution of defined steps of in-
flammasome activation in vitro or in unrelated control cells 
has been quite informative, but—short of their deletion, 
mutation, or overexpression—inflammasome components 
in their physiological context are challenging targets for 
molecular perturbations. Many inflammasome components 
are prone to oligomerization, or self-activate when artifi-
cially overexpressed (Fernandes-Alnemri et al., 2007; She-
noy et al., 2012), emphasizing the need for functional studies 
in relevant cell types with endogenous expression levels of 
inflammasome components.
Antibodies are valuable tools to perturb protein func-
tion in vitro, or when microinjected into living cells (Doxsey 
et al., 1987; Antonin et al., 2000). Nonetheless, application 
of full-sized antibodies has been limited to a few select cases, 
mostly because of technical challenges. These include the 
time required to generate and produce antibodies, their bulk, 
inefficient delivery methods, and sensitivity to the reducing 
environment of the cytosol.
The description of heavy chain-only antibodies in 
camelids was a landmark discovery (Hamers-Casterman et 
al., 1993; Helma et al., 2015) that provided a means to over-
come many of these challenges. Heavy chain-only antibodies 
are comprised of two identical heavy chains and recognize 
their antigen by means of a single, heavy chain variable 
domain (VHH). These VHH segments can be expressed as 
stand-alone fragments and exhibit affinities comparable to 
conventional antibodies. VHHs are stable in the absence of 
disulfide bonds or glycosylation and can thus be easily pro-
duced in bacteria or expressed in the cytosol of eukaryotic 
cells (Muyldermans, 2013). VHHs have been used as crystal-
lization chaperones owing to their ability to stabilize pro-
tein structures (Pardon et al., 2014; Burg et al., 2015). VHHs 
can induce or selectively bind distinct conformations, mask 
epitopes required for protein–protein interactions, or inhibit 
enzymatic activities (Kirchhofer et al., 2010; Paalanen et al., 
2011; Irannejad et al., 2013). VHHs directed against distinct 
inflammasome components would thus constitute excel-
lent tools to probe and molecularly analyze specific steps of 
inflammasome activation.
We generated a VHH against the adaptor protein ASC 
to elucidate the molecular mechanism that allows ASC to 
greatly amplify the signaling response to many inflammasome 
triggers. We show that VHHASC specifically blocks CARD–
CARD interactions of ASCCARD, and thus inhibits inflam-
masome activation by agents that trigger NLRP3, AIM2, 
and NAIP in human macrophage-like cells. By stabilizing 
an intermediate step of inflammasome activation, VHHASC 
confirmed the formation of ASCPYD filaments at endogenous 
ASC levels, and revealed that ASC CARD mediates the co-
alescence of multiple ASC filaments into a single macromo-
lecular ASC focus per cell.
RES ULTS
Identification of an alpaca VHH specific for human ASC
To study molecular interactions in the course of inflam-
masome activation, we generated alpaca VHHs that bind to 
the adaptor protein ASC. We immunized an alpaca with pu-
rified ASC, produced as a fusion with maltose-binding pro-
tein (MBP). After five booster immunizations, we isolated 
peripheral blood lymphocytes from the immunized alpaca, 
extracted RNA, prepared cDNA, and amplified VHH-coding 
sequences by PCR. The amplified VHH cDNAs were cloned 
into a phagemid vector to yield a plasmid library that encodes 
the VHH repertoire contained in the collected lymphocytes.
To identify VHHs that bind human ASC, we immobilized 
MBP-ASC to beads and selected ASC-binding phage by two 
rounds of phage display. Because we observed a strong immune 
response to MBP, we depleted phages displaying MBP-binding 
VHHs before each round of phage display and panned for 
ASC-specific VHHs in the presence of excess soluble MBP. 96 
VHH clones obtained by this procedure were sequenced and 
tested by ELI SA for binding to the fusion protein MBP-ASC 
and MBP alone. Of these 96 clones, 43 bound to MBP-ASC, 
but not to MBP, and all encoded the same VHH, VHHASC.
To test its specificity, we expressed VHHASC in Escherichia 
coli and coupled the purified VHHASC to cyanogen bromide- 
activated Sepharose beads. Incubation of this VHHASC matrix 
with lysates of THP-1 cells that overexpress EGFP allowed 
recovery of a single predominant polypeptide with an appar-
ent molecular weight of 20 kD (Fig. 1 A). The identity of this 
polypeptide as ASC was confirmed by mass spectrometry (80% 
sequence coverage; unpublished data). A similarly immobilized 
GFP-specific VHH, VHHEnhancer (Kirchhofer et al., 2010), recov-
ered EGFP but not ASC from the same THP-1 lysates. VHHASC 
thus interacts specifically with ASC in THP-1 cell lysates.
The VHH expression vectors encode VHHs equipped 
with a sortase motif to facilitate site-specific labeling with 
organic fluorophores. Fluorescently labeled VHHASC specif-
ically stained ASC foci in THP-1 cells evoked by treatment 
with the NLRP3 activators LPS and nigericin, but did not 
stain any distinct structures in untreated cells (Fig. 1 B). A 
fluorescently labeled control VHH specific for the influenza 
A virus nucleoprotein, VHH NP1 (Ashour et al., 2015), 
did not stain ASC foci.
We applied the LUM IER assay (Barrios-Rodiles et al., 
2005) to test interactions of HA-tagged VHHASC with Re-
nilla luciferase fused to human and mouse full-length ASC, 
as well as fusions of Renilla with the individual domains 
of human ASC, ASCPYD, and ASCCARD. Full-length human 
ASC and ASCCARD interacted with VHHASC, whereas mu-
rine ASC and the PYD of human ASC did not (Fig. 1 C). 
We concluded that VHHASC recognizes the CARD of 
human ASC. VHHASC also recognized ASC CARD in im-
munoblots (Fig. 1 E), indicating that the epitope recognized 
by VHHASC is retained in SDS-treated ASCCARD. Moreover, 
purified VHHASC, when mixed with MBP-ASCCARD, en-
gaged in complex formation and co-eluted with MBP- 
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ASCCARD upon size-exclusion chromatography (Fig. 1 D). 
Size-exclusion chromatography showed co-elution of 
ASCCARD and VHHASC at an estimated 1:1 stoichiome-
try. We concluded that VHHASC specifically binds to the 
CARD of human ASC, but not mouse ASC.
Structures of VHHASC alone and 
the ASCCARD–VHHASC complex
To map the molecular interactions between VHHASC and 
ASC, we determined the crystal structures of VHHASC alone 
and in complex with ASCCARD at 1.9 and 4.2 Å resolution, 
Figure 1. VHHASC specifically binds human ASC CARD. (A) Resins with covalently coupled VHHASC and VHHEnhancer were used to immunoprecipitate the 
respective VHH targets from THP-1 cells expressing EGFP. Proteins bound to the resin were eluted with acidic buffers, separated by SDS-PAGE, and stained 
with colloidal Coomassie. The highlighted protein bands were cut out and subjected identification by mass spectrometry. (B) Differentiated THP-1 cells 
were left untreated or treated with LPS and nigericin to trigger NLRP3 inflammasome activation. Cells were subjected to immunofluorescence staining with 
rabbit anti-ASC and Alexa Fluor 647–coupled VHHASC or VHH NP1. Maximum intensity projections of representative images of at least three experiments 
are presented. Bars, 10 µm. (C) A549 cells transiently expressing HA-tagged VHHs and the designated bait proteins fused to Renilla luciferase were lysed 
to immunoprecipitate VHHs with immobilized anti-HA. Renilla luciferase activity of the coimmunoprecipitated proteins was measured and normalized by 
the activity in the input. Mean values ± SEM from three independent experiments are displayed. (D) MBP-ASCCARD was incubated with an excess of VHHASC 
and complexes separated from monomeric VHHASC by size-exclusion chromatography. MBP was cleaved off purified complexes with TEV protease, and the 
yielded protein samples were subjected to size-exclusion chromatography as well. Samples of the fractions were analyzed by SDS-PAGE and Coomassie 
staining. (E) A549 cells were transiently transfected with expression vectors for EGFP, EGFP-ASC, EGFP-ASCPYD, or EGFP-ASCCARD. 24 h after transfection, cells 
were lysed and subjected to SDS-PAGE and immunoblot with anti-EGFP, anti-ASC (raised against the PYD of ASC), and VHHASC combined with the respective 
HRP-coupled secondary antibodies. Representative immunoblots of at least three experiments are shown.
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respectively (Table S1 and Table S2). The VHHASC structure 
shows the typical features of a V domain fold, comprised of 
nine β-strands stacked into a four-stranded β-sheet and a 
five-stranded β-sheet (Fig. 2 A). The four-stranded β-sheet is 
formed by β-strands A/A′, B, E, and D, and the five-stranded 
β-sheet is formed by β-strands C, C′, C′′, F, and G, which are 
connected by intervening loops. The loop regions connect-
ing β-strands B and C, strands C′ and C′′, and strands F and 
G correspond to the complementarity-determining regions 
CDR1, CDR2, and CDR3, respectively. Compared with 
other VHHs, VHHASC exhibits an unusually short CDR3. We 
inferred that the very short CDR3 in VHHASC is unlikely to 
make a major contribution to binding its target.
To determine the binding interface with ASC, we de-
termined the crystal structure of VHHASC in complex with 
ASCCARD. We were not successful in crystallizing the wild-
type ASCCARD–VHHASC complex, and instead turned to a 
monomeric mutant (N128A/E130R) of ASCCARD. These 
mutations were predicted to impair CARD–CARD interac-
tions via the type IIb interface based on the rather conserved 
interaction surfaces in the death domain family (Lin et al., 
2010; Ferrao and Wu, 2012). The mutant ASCCARD remained 
monomeric, could still form a complex with VHHASC, and 
crystallized into needle-shaped crystals, which allowed us to 
solve the structure (Fig. 2 B).
Compared with the crystal structure of VHHASC alone 
and the NMR structure of ASC (Research Collaboratory for 
Structural Bioinformatics Protein Data Base code [RCSB 
PDB]: 2KN6; de Alba, 2009), neither VHHASC nor ASCCARD 
in the VHHASC–ASCCARD complex shows significant confor-
mational changes (Fig.  2 C). Even though the structure of 
the complex was determined only to near-atomic resolution, 
it nonetheless allowed identification of residues in contact. 
Surprisingly, among the CDRs, only the CDR2 loop par-
ticipates in ASC recognition (Fig. 2 B). In addition, the C′ 
strand and the C′′ strand of VHHASC, which correspond to 
frameworks 2 and 3 of the domain, respectively, constitute the 
majority of the interface with ASC (Fig. 2 B). On the side of 
ASCCARD, the last helix α6 and, less extensively, α1, directly 
contact VHHASC. Residues Thr57, Tyr59, Arg50, and Asp62 
of VHHASC interact with residues Arg194, Glu190, Asp191, 
Arg125, Tyr187, and Gln185 of ASCCARD to form the bind-
ing interface. Importantly, the exposed Tyr187 on ASCCARD 
is completely masked by VHHASC, and this hydrophobic in-
teraction with a large buried surface area presumably con-
tributes significantly to the binding affinity (Figs. 2 B and 
3 A). Collectively, our structural analysis shows that VHHASC 
mostly binds to the C-terminal region of human ASC, using 
an unusual combination of CDR2 and framework residues.
Binding of VHHASC to ASCCARD sterically occludes 
ASCCARD type II interface
To understand the molecular interaction between ASCCARD and 
VHHASC, as well as the implications for the effect of VHHASC 
in inhibiting ASCCARD-mediated interactions, we attempted 
to identify the surfaces of ASCCARD that mediate interactions 
with itself and with caspase-1CARD. We first investigated the 
quaternary structure assumed by oligomers of ASCCARD. We 
constructed a sandwich-tagged MBP-ASCCARD-SUMO fu-
sion protein. Upon removal of MBP, ASCCARD-SUMO oligo-
merized into extended filaments (Fig. 3 B). The SUMO fusion 
prevents aggregation of filaments and increased overall solubil-
ity after oligomerization. Irrespective of whether endogenous 
ASCCARD forms extended filaments or short filamentous as-
semblies under physiological conditions in cells, the ASCCARD 
Figure 2. VHHASC binds to an interface of ASCCARD that is required 
for CARD–CARD interactions. (A) Structure of VHHASC at 1.9 Å resolu-
tion. (B) Structure of VHHASC in complex with the N128A/E130R monomeric 
mutant of ASCCARD at 4.2 Å resolution. Residues at the interaction interface 
are indicated. Because the resolution of the complex was not sufficient 
to resolve the displayed amino acid side chains, we used the side chain 
conformations from the VHH crystal structure at 1.9 Å resolution and the 
full-length ASC NMR structure. (C) Comparisons of the structures of the 
complex of VHHASC/ASCCARD N128A/E130R with VHHASC and ASCCARD alone.
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filaments formed in vitro serve as a proxy that helps reveal struc-
tural details of CARD–CARD interactions. No structural in-
formation on the filamentous structure of ASCCARD exists, but 
CARD domains exhibit a sufficient degree of conservation to 
allow meaningful structural predictions based on other CARD 
structures. We therefore modeled the structure of an ASCCARD 
filament based on the 3.6 Å resolution cryo-EM structure of 
the MAVSCARD filament (Wu et al., 2014). We aligned copies of 
ASCCARD to each unit of the MAVSCARD filament, effectively 
imposing the one-stranded helical parameters (101.1° twist 
angle and 5.13 Å axial rise per unit) onto ASCCARD. We then 
superimposed the VHHASC–ASCCARD complex structure on 
the predicted ASCCARD filament structure (Fig. 3 C). Thus, the 
surface of ASCCARD used in the VHHASC interaction overlaps 
with its type IIb surface; the bound VHHASC sterically clashes 
with the adjacent subunit in the ASCCARD filament along 
the type II direction, suggesting that binding of VHHASC to 
ASCCARD interferes with CARD–CARD interactions in 
ASCCARD self-oligomerization via the type II interface.
ASCCARD and Caspase-1CARD also interact 
through type II interfaces
To probe the importance of the type II interface of ASCCARD, 
we analyzed the effect of mutations at this interface on 
ASCCARD interaction with pro–caspase-1CARD. The VHHASC–
ASCCARD complex structure shows a hydrophobic surface 
patch near α6, primarily contributed by the exposed Tyr187 
(Fig. 3 A). We generated the Y187A mutant in full-length ASC 
fused to the C terminus of solubilizing MBP, and cleaved off 
Figure 3. Binding of VHHASC to ASCCARD 
sterically occludes ASCCARD type II inter-
face. (A) Electrostatic surface representation 
of the VHHASC–ASCCARD complex, highlighting 
tyrosine 59 in VHHASC and tyrosine 187 in 
ASCCARD. (B) The MBP-ASCCARD-SUMO fusion 
protein was incubated with TEV protease to 
cleave off the MBP protein, which led to po-
lymerization of ASCCARD-SUMO. A representa-
tive electron micrograph of the resulting fibers 
subjected to negative staining is shown. Bar, 
100 nm. (C) Representation of the ASCCARD 
filament modeled using the known MAVSCARD 
filament structure (left), a zoomed view of the 
type II interface of two highlighted ASCCARD 
subunits (middle), and illustration of the 
complex of VHHASC with ASCCARD subunit 1 
(right). The VHH sterically clashes with ASCCARD 
subunit 2 bound via the type II interface 
(shown in transparent cyan). (D) Interaction of 
ASC WT and type II mutant Y187A with His-
tagged caspase-1. The indicated combinations 
of His6-GFP-caspase-1CARD and WT or mutant 
His6-MBP-ASC were incubated. Where indi-
cated, His6-MBP was cleaved off ASC using TEV 
protease, and His-tagged proteins were puri-
fied using Ni-NTA resin. Samples of the pro-
tein mixtures were analyzed by SDS-PAGE and 
Coomassie staining. Positions of the indicated 
proteins are marked on the right. The intensity 
of the ASCFL bands was determined from the 
scanned gel and normalized by the band inten-
sity of GFP-caspase-1CARD.
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MBP in the presence of His6-GFP-caspase-1CARD. When we 
purified His6-GFP-caspase-1CARD with Ni-NTA resin, the 
amount of the ASC mutant co-purified was reduced by 63% 
compared with wild-type ASC (Fig. 3 D). We concluded that 
type II interactions are essential in mediating the ASCCARD–
caspase-1CARD association. Blocking this interface by VHHASC 
was thus expected to abolish ASCCARD self-oligomerization, as 
well as its ability to recruit pro–caspase-1.
VHHASC directly inhibits ASCCARD-nucleated Caspase-1CARD 
and ASCCARD polymerization
We can reconstitute the polymerization of inflammasome 
components in vitro using purified proteins, including the 
ASCCARD-nucleated polymerization of caspase-1CARD (Lu et 
al., 2014). We used a fluorescence polarization assay to mon-
itor nucleation of caspase-1CARD filaments by oligomeric 
ASCCARD in the presence and absence of VHHASC (Fig. 4 A). 
This assay exploits the fact that fluorescence anisotropy in-
creases when a fluorescent monomeric species polymerizes. 
In short, we labeled monomeric caspase-1CARD (N-terminal 
MBP, C-terminal SUMO) by means of a sortase reaction 
(Guimaraes et al., 2013), followed by purification of the la-
beled monomers (Lu et al., 2014). We added substoichio-
metric amounts of oligomeric GFP-ASCCARD to seed the 
growth of caspase-1CARD filaments upon tobacco etch virus 
(TEV) protease cleavage of the MBP fusion partner. We pre-
incubated the GFP-ASCCARD seeds with either VHHASC or 
the anti-GFP VHHEnhancer. Incubation of the GFP-ASCCARD 
seeds with equimolar amounts of VHHASC abolished their 
ability to nucleate caspase-1CARD filament formation 
(Fig. 4 A). Incubation of GFP-ASCCARD with VHHEnhancer 
did not affect caspase-1CARD polymerization. Binding of 
ASCCARD by VHHASC thus directly and specifically interferes 
with the ASCCARD–capase-1CARD interaction.
To determine the stoichiometry of inhibition by VHHASC, 
we preincubated a fixed, substoichiometric amount of ASCCARD 
with various amounts of VHHASC, and subsequently moni-
tored caspase-1CARD filament formation (Fig. 4 B). We fitted 
a single-site antagonist model to the obtained initial slopes of 
the fluorescence polarization traces and determined the ap-
parent binding constant (Kapp) between VHHASC and GFP- 
ASCCARD to be 159.5 ± 1.5 nM (Fig. 4 C). Kapp is of the same 
order of magnitude as the concentration of GFP-ASCCARD, 
suggesting that 1:1 binding of VHHASC inhibits ASCCARD–
caspase-1CARD interaction.
In addition, we assayed the effect of VHHASC directly on 
ASCCARD oligomerization. We used fluorescently labeled mo-
Figure 4. VHHASC prevents ASCCARD-nucleated polymerization of caspase-1CARD and ASCCARD. (A) ASC-nucleated caspase-1CARD polymerization in the 
presence of VHHASC and VHHEnhancer. Fluorescently labeled monomeric MBP-caspase-1CARD-SUMO (4 µM) was mixed with oligomeric GFP-ASCCARD (1.1 µM) 
preincubated with VHHASC or VHHEnhancer (1.1 µM) where indicated. MBP was cleaved from fluorescent caspase-1CARD-SUMO to allow ASCCARD-nucleated 
polymerization of caspase-1CARD. Polymerization was followed by measuring fluorescence polarization over time. (B) ASC-nucleated caspase-1CARD polym-
erization in presence of different VHHASC concentration. Polymerization of caspase-1CARD-SUMO by oligomeric GFP-ASCCARD was measured by fluorescence 
polymerization assays as described in A, except that GFP-ASCCARD was preincubated with the indicated concentrations of VHHASC. (C) Apparent inhibition 
constant of VHHASC. The initial slope of the fluorescence polarization processes in B was plotted against the logarithm of the VHHASC concentration. 
A single-site antagonist model was fitted to this plot to extract the apparent inhibition constant Kapp. (D) ASCCARD polymerization. Fluorescently labeled 
monomeric MBP-ASCCARD-SUMO (5 µM) was preincubated with VHHASC at the indicated concentrations. MBP was cleaved off fluorescent ASCCARD-SUMO to 
self-nucleated polymerization of ASCCARD. Polymerization was followed by measuring fluorescence polarization over time. (E) Stability of ASCCARD oligomers 
in presence of VHHASC. Oligomeric GFP-ASCCARD was incubated with excess VHHASC for 30 min at room temperature or left untreated. Protein samples were 
subsequently subjected to size-exclusion chromatography. OD280 profiles are displayed.
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nomeric MBP-ASCCARD-SUMO in an experiment similar to 
the caspase-1CARD polymerization assay, but exploited the fact 
that, at sufficient concentrations, ASCCARD-SUMO polymer-
izes in the absence of any nucleators. Addition of an approx-
imately equimolar amount of VHHASC to the polymerizing 
ASCCARD was required to block polymerization (Fig.  4  D), 
suggesting that 1:1 binding of VHHASC to ASCCARD also inhib-
its its self-oligomerization. To compare the affinity of VHHASC 
for ASCCARD with the affinities of ASC CARD–CARD inter-
actions, we incubated oligomeric GFP-ASCCARD with excess 
VHHASC. GFP-ASCCARD on its own behaves as an oligomer 
as assayed by size-exclusion chromatography. After incubation 
with excess VHHASC, however, only smaller dimeric complexes 
of ASCCARD–VHHASC as well as monomeric VHHASC, were 
observed (Fig. 4 E), suggesting that VHHASC may even disas-
semble already activated inflammasome complexes by compet-
ing with ASC CARD–CARD interactions. Collectively, the 
data demonstrate that VHHASC—by occluding the type IIb in-
terface of ASCCARD—perturbs CARD–CARD interactions of 
ASCCARD with both ASCCARD and caspase-1CARD.
VHHASC blocks NLRP3- and AIM2-dependent 
inflammasome activation
In contrast to conventional antibodies, VHHs can retain their 
binding properties in the reducing milieu of the cytosol. 
VHHs can therefore be expressed cytosolically to perturb 
protein function under physiological conditions and at en-
dogenous concentrations of the wild-type form of a VHH 
target (Ashour et al., 2015; Helma et al., 2015). In this sense, 
VHH-mediated perturbations are fundamentally distinct 
from analyses of mutant forms of the target protein, or from 
siRNA or Cas9/CRI SPR-based approaches where the goal 
is a reduction in expression levels of the target protein.
To study the role of ASC CARD during inflammasome 
assembly in human cells, we generated derivatives of the 
human monocyte-like cell line THP-1 that inducibly express 
HA-tagged VHHASC or the control VHH NP1 (Ashour et al., 
2015) upon addition of doxycycline. Both VHHs were in-
duced to similar levels of expression (Fig. 5 A), did not alter 
levels of ASC (Fig. 5 B), and did not affect LPS-induced TNF 
secretion in phorbol-12-myristate-13-acetate (PMA)–dif-
ferentiated cells (Fig. 5 C). To test the effect of VHHASC on 
NLRP3 inflammasome activation, we differentiated THP-1 
cells with PMA over night, and then induced VHH expres-
sion for 24 h. For activation, doxycycline-induced cells were 
treated with LPS for 3 h and with the potassium ionophore 
nigericin for 45 min, both in the absence of doxycycline.
Potassium efflux activates the NLRP3 inflammasome. 
This involves the recruitment and polymerization of ASC and 
pro–caspase-1, autocatalytic activation of caspase-1, and sub-
sequent maturation of IL-1β and -18. As assessed by immu-
noblot and ELI SA, parental THP-1 cells secreted processed 
caspase-1 and IL-1β in response to NLRP3 triggers (Fig. 5, D 
and E). Doxycycline treatment did not affect caspase-1 acti-
vation or IL-1β conversion. Moreover, on average, 58% of the 
cells contained an ASC focus as detected by immunofluores-
cence microscopy using anti-ASC antibodies (Fig. 5, F and G). 
Although VHHASC cell lines behaved like unmodified THP-1 
cells in the absence of doxycycline, caspase-1 cleavage and 
IL-1β secretion were substantially reduced in cells induced 
to express VHHASC. Only 10% of the treated cells contained 
an ASC focus when expression of VHHASC was induced. In-
duction of the control VHH NP1 neither changed secretion 
of caspase-1 and IL-1β, nor substantially impaired ASC focus 
formation. VHHASC thus specifically reduces the assembly 
of ASC foci and perturbs the recruitment and autocatalytic 
cleavage of pro–caspase-1 and, consequently, IL-1β secretion.
When activated by DNA, AIM2 employs ASC to recruit 
and activate pro–caspase-1 similar to NLRP3. When THP-1 
cell lines were transfected with poly(dA:dT), IL-1β release 
was substantially reduced by expression of VHHASC, but not 
by the control VHH NP1 (Fig.  5 H). Consistent with our 
interpretation of the in vitro data, VHHASC masks the CARD 
of soluble ASC molecules in living cells and thus prevents 
CARD–CARD interactions between ASC molecules and re-
cruitment of pro–caspase-1.
VHHASC blocks NAIP/NLRC4-dependent 
inflammasome activation
Whereas NLRP3 and AIM2 receptors depend on ASC to 
recruit pro–caspase-1 to nascent inflammasomes, NAIP–
NLRC4 inflammasome complexes can directly engage pro–
caspase-1 via homotypic CARD–CARD interactions. In 
mouse cells, NLRC4-dependent secretion of IL-1β is more 
efficient in the presence of ASC (Broz et al., 2010a). To inves-
tigate the role of ASC in NAIP/NLRC4 inflammasomes in 
human cells, we differentiated THP-1 cell lines and activated 
NAIP/NLRC4 inflammasomes with the Shigella flexneri 
needle protein MxiH, which directly binds to NAIP and thus 
activates NAIP/NLRC4 inflammasomes (Yang et al., 2013). 
MxiH was delivered into the cytosol using the anthrax toxin 
delivery system (Arora and Leppla, 1993; Young and Collier, 
2007). In brief, cells were treated with the anthrax toxin pro-
tective antigen (PA) and a fusion protein of MxiH and the N 
terminus of the anthrax lethal factor, LFn. PA binds to the an-
thrax receptor at the cell surface, is proteolytically activated to 
form the prepore, and then recruits LFn-MxiH. The complex 
is endocytosed and LFn-MxiH is translocated into the cytosol 
through the PA pore upon acidification of endosomes.
In parental THP-1 cells, translocation of MxiH to 
the cytosol induced robust IL-1β secretion and pyroptotic 
cell death, as judged by release of cytosolic LDH (Fig.  6, 
A and B). To show that the observed IL-1β secretion and 
pyroptotic cell death were indeed dependent on MxiH, and 
not caused by bacterial contaminants contained in our pro-
tein preparations, we used a mutant version of MxiH. The 
mutant MxiH 2A, in which two conserved hydrophobic 
residues in the needle protein helical hairpin region were 
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changed to alanine (Yang et al., 2013), was indeed substan-
tially less potent than MxiH in activating IL-1β secretion 
and cell death. In cells expressing VHHASC, cytokine secre-
tion was clearly diminished in response to MxiH delivery, 
whereas control cells that expressed VHH NP1 behaved 
like the parental THP-1 line. Human NAIP/NLRC4 in-
flammasome activation thus requires ASC for efficient cy-
tokine maturation. IL-1β secretion was diminished slightly 
in THP-1 VHHASC cells in which VHH expression was not 
induced. This is most likely caused by leakiness of the in-
ducible expression system.
In parental THP-1 cells and THP-1 cell lines express-
ing VHH NP1, we observed ASC foci in 37 and 44% of the 
treated cells (Fig. 6, C and D). In THP-1 cells that express 
VHHASC, the fraction of cells containing ASC foci was re-
duced to 13%. As is the case for NLRP3 inflammasomes, 
VHHASC acted both at the level of ASC focus formation and 
in the recruitment of pro–caspase-1 to perturb activation of 
NAIP/NLRC4 inflammasomes.
In contrast to cytokine secretion, cell death by pyropto-
sis occurred at comparable levels in THP-1, THP VHHASC, 
and THP VHH NP1, irrespective of whether VHH expres-
sion was induced or not. This suggests that human ASC is dis-
pensable for pyroptosis. Direct pro–caspase-1 recruitment to 
NLRC4 may be sufficient for cell death, as has been proposed 
for mouse macrophages infected with Salmonella (Broz et al., 
2010b). In summary, our data suggest that NLRC4-depen-
dent IL-1β maturation and secretion requires ASC. Caspase-1 
activation very likely takes place at the macromolecular as-
semblies visualized as ASC foci. In contrast, cell death by py-
roptosis does not require ASC or ASC foci, and is presumably 
initiated in smaller assemblies.
Figure 5. VHHASC prevents activation of 
NLRP3 and AIM2 inflammasomes in THP-1 
cells. (A) THP-1 cell lines inducibly expressing 
VHHASC-HA or VHH NP1-HA were cultivated for 
24 h in the absence or presence of doxycycline, 
fixed, stained for HA, and analyzed by flow cy-
tometry. (B–E) Wild-type THP-1 cells and the 
cell lines described in A were differentiated and 
VHH expression induced for 24 h. (B) Cells were 
treated with 200 ng/ml LPS for 3 h, harvested, 
and cell lysates analyzed by immunoblot with 
anti-ASC, anti-HA, and anti-GAP DH. (C) Cells 
were treated with 200 ng/ml LPS for 4 h or left 
untreated. Supernatants were analyzed by TNF 
ELI SA. (D and E) Cells were treated with LPS 
for 3  h and nigericin for 45 min, or left un-
treated. Supernatants were analyzed by IL-1β 
ELI SA (D) and by immunoblots with anti–IL-1β 
and anti-caspase-1 p10 (E). Immunoblots rep-
resentative of three experiments are shown. 
The asterisk indicates a statistically significant 
difference (Student‘s t test; P < 0.001). (F and 
G) Cells treated as in D were fixed and stained 
for DNA and ASC; images were recorded by 
wide field fluorescence microscopy (F) and the 
fraction of cells containing ASC foci was quan-
tified (G). Data from three independent exper-
iments with at least 500 cells per condition ± 
SEM is shown. Bars, 20 µm. (H) THP-1 cell lines 
cultivated as described in B were treated with 
LPS for 3 h and transfected with poly (dA:dT) 
or transfection agent only. Supernatants were 
harvested after 4  h and IL-1β levels were 
quantified by ELI SA. The asterisk indicates a 
statistically significant difference (Student‘s t 
test; P = 0.002). Data from three independent 
experiments was quantified for all ELI SA re-
sults and mean values ± SEM are shown.
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VHHASC-EGFP assembles along ASC filaments in response to 
NLRP3 and AIM2 activators
In the presence of VHHASC-HA, we observed reduced num-
bers of ASC foci in response to NLRP3 triggers. Given that 
VHHASC binds to the CARD of ASC, and that NLRP3 ac-
tivation induces the formation of ASCPYD filaments in vitro, 
we were surprised that we were unable to stain any macro-
molecular structures containing ASC or VHHASC-HA in cells 
that lacked ASC foci. Because we used conventional indirect 
immunofluorescence microscopy with primary antibodies 
against the PYD of ASC or against HA in combination with 
fluorescently-labeled secondary antibodies, we reasoned that 
impaired accessibility of antigens for staining with conven-
tional antibodies, or the small number of molecules involved 
might be the explanation.
To address these issues, we generated THP-1 cell lines 
that inducibly expressed a VHHASC-EGFP fusion protein or 
the control VHH NP1-EGFP. When THP-1 VHHASC-EGFP 
cells were treated with LPS and nigericin to activate NLRP3 
inflammasomes, we observed two different outcomes (Fig. 7, 
B and E): few cells contained ASC foci that could be stained 
with conventional anti-ASC antibodies and that were EGFP 
positive—they presumably represent the fraction of cells in 
which VHH levels were too low to impair ASC focus for-
mation, but in which VHHASC may still impair pro–caspase-1 
recruitment. We also observed many cells that exhibited one, 
a few, or multiple filamentous EGFP structures of variable 
length that could not be stained with ASC PYD antibod-
ies. In the absence of inflammasome triggers, cells that ex-
pressed VHHASC-EGFP lacked such structures (Fig. 7, A and 
E). Filamentous structures were absent also from cells that 
expressed the control VHH NP1-EGFP, even when treated 
with NLRP3 inflammasome triggers. Filamentous EGFP was 
thus observed only upon meeting two conditions: (1) when 
ASCPYD could build filaments in response to inflammasome 
triggers and (2) when VHHASC-EGFP was expressed. We 
conclude that these EGFP-positive structures were formed 
along endogenous ASC filaments, assembled upon NLRP3- 
nucleated polymerization of ASCPYD. We hypothesize that 
an excess of VHHASC-EGFP thus masked ASCCARD, but still 
permitted the formation of ASCPYD filaments. This is the first 
time that ASC filaments could be visualized at physiological 
ASC levels and therefore cannot be attributed to overexpres-
sion artifacts. These filaments must represent an intermediate 
phenotype, as ASCCARD was masked by VHHASC and could 
not complete its physiological function. That ASC formed 
long, unbranched filaments, as opposed to densely packed 
ASC foci, suggests that the organization of multiple ASC fil-
Figure 6. VHHASC prevents IL-1β secretion, but not cell death, by NAIP/NLRC4 inflammasomes in THP-1 cells. (A and B) WT THP-1 cells and cell 
lines inducibly expressing VHHASC-HA or VHH NP1-HA were differentiated and VHH expression induced for 24 h. Cells were treated with PA and LFn-MxiH 
WT or 2A for 3 h or left untreated. IL-1β in the supernatants was quantified by ELI SA (A), LDH activity was quantified and normalized to cells lysed in 1% 
Triton X-100 (B). Data from three independent experiments was quantified and mean values ± SEM are shown. The asterisk indicates a statistical significant 
difference (Student‘s t test; P = 0.039). (C and D) THP-1 cell lines were differentiated and induced as described in A, and subsequently treated with PA and 
MxiH WT or 2A for 2 h in the presence of 50 µM z-YVAD-cmk. Cells were fixed and stained for DNA and ASC; images were recorded by wide field fluores-
cence microscopy (C) and the fraction of cells containing ASC foci was quantified (D). Bars, 20 µm. Data from three independent experiments with at least 
500 cells per condition ± SEM is shown.
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aments into a single focus requires accessible ASCCARD. The 
ASCCARD, beyond its role in the recruitment of pro–caspase-1, 
thus serves a function in the organization of multiple ASC fil-
aments into a single dense ASC focus, possibly by cross-linking 
ASC filaments assembled through the ASCPYD.
In vitro, full-length ASC assembles into highly cross-
linked filaments, while ASCPYD assembled into long, linear 
filaments (Cai et al., 2014; Lu et al., 2014). If VHHASC-EGFP 
indeed prevented cross-linking of full-length ASC filaments 
(vide supra), VHHASC should also prevent cross-linking of 
ASC filaments in vitro. To test the effect of VHHASC on the 
quaternary structure of full-length ASC, we formed a com-
plex of VHHASC and recombinantly expressed full-length 
ASC fused to MBP, in which MBP prevents ASC oligomer-
ization. When MBP was removed from the complex by TEV 
protease cleavage, ASC/VHHASC polymerized into long, 
linear filaments as observed by negative-stain EM after only 
5 min (Fig.  8  A). These filaments have a diameter of >20 
Å, corresponding to a core PYD filament (≈9 Å; Lu et al., 
2014) decorated by ASCCARD–VHHASC monomers. Impor-
tantly, these filaments are not cross-linked, and thus resemble 
ASCPYD filaments. When MBP was cleaved from MBP-ASC 
in the absence of VHHASC, ASC polymerized as well, but 
formed highly cross-linked bundled structures which precipi-
tated over time. After 20 min, essentially no more filamentous 
structures were recognized and ASC formed an amorphous, 
dense mass. By masking the ASCCARD, VHHASC therefore may 
prevent cross-linking of full-length ASC filaments in vitro, in 
support of the model deduced from our microscopy studies.
To more directly visualize ASC in the observed fila-
mentous assemblies, we took advantage of the propensity of 
overexpressed EGFP-ASC to assemble into ASC foci when 
Figure 7. VHHASC-EGFP assembles along 
ASC filaments in response to inflammasome 
triggers. (A–D) THP-1 cell lines inducibly ex-
pressing VHHASC-EGFP or VHH NP1-EGFP were 
differentiated and VHH expression induced for 
24 h. Cells were left untreated (A), treated with 
LPS for 3 h and nigericin for 45 min to trigger 
NLRP3 inflammasomes (B), treated with LPS 
for 3 h and transfected with DNA for 4 h to 
trigger AIM2 inflammasomes (C), or treated 
with PA and LFn-MxiH WT in the presence of 
30  µM z-YVAD-cmk for 2  h to trigger NAIP/
NLRC4 inflammasomes (D). Cells were fixed 
and stained for DNA and ASC; images of single 
planes were recorded by spinning disc confo-
cal microscopy. Bars, 10 µm. Representative 
images from at least three experiments are 
shown. (E–G) THP-1 cell lines were differen-
tiated, VHH expression induced, and NLRP3, 
AIM2, and NLRC4 inflammasomes activated or 
cells left untreated as in A–D, but in the pres-
ence of 50 µM z-YVAD-cmk. Cells were fixed 
and mounted with mounting medium contain-
ing DAPI; Z stacks were recorded by spinning 
disc confocal microscopy. At least 300 cells 
per condition were analyzed and cells contain-
ing green-fluorescent filaments or foci were 
manually counted. One typical experiment 
representative of at least three independent 
experiments was quantified.
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overexpressed in epithelial cells (Masumoto et al., 2001a). Al-
though nucleation of EGFP-ASC foci themselves is artificial 
and does not depend on any upstream nucleators, formation 
of the macromolecular structures seems to be governed by 
the PYD/PYD and CARD–CARD interactions that are as-
sumed to underlie the assembly of endogenous ASC foci (Lu 
et al., 2014; Sahillioglu et al., 2014). This includes the find-
ing that EGFP-ASCPYD assembles into filaments, as it does 
in vitro. When EGFP-ASC or EGFP-ASCPYD was overex-
pressed in epithelial A549 cells, we observed foci and fila-
ments, respectively (Fig. 8 B). When full-length EGFP-ASC 
was expressed in the presence of VHHASC, however, we did 
observe EGFP-ASC filaments but no ASC foci. These fila-
ments resembled the EGFP-ASCPYD filaments, indicating that 
in masking ASCCARD, VHHASC blocked further compaction 
of ASC filaments formed by PYD polymerization.
Activation of AIM2 by DNA-binding nucleates the for-
mation of ASC PYD filaments in vitro, too (Lu et al., 2014). 
To validate our model, we tested whether DNA—as an al-
ternative activator of ASC PYD filaments—would also lead 
to the assembly of VHHASC-EGFP along endogenous ASC 
structures in a cellular context (Fig.  7, C and F). Indeed, 
we observed filamentous EGFP in poly(dA:dT)-transfected 
THP-1 cells expressing VHHASC-EGFP, but not in cells ex-
Figure 8. VHHASC stabilizes ASC filaments formed through ASCPYD polymerization in vitro and in cells. (A) MBP-ASC or MBP-ASC preincubated 
with VHHASC was incubated with TEV protease to remove the MBP fusion and allow polymerization. At the indicated times, the reaction was stopped and 
the resulting macromolecular structures were visualized by negative stain electron microscopy. Bars, 500 nm. (B) A549 cells were transiently transfected 
with expression vectors for EGFP-ASCPYD or EGFP-ASC in the absence or presence of expression vectors for VHHASC or VHH NP1. 24 h after transfection, cells 
were fixed and stained for DNA and filamentous actin. Z-stacks of representative cells were recorded by spinning disc confocal microscopy and maximum 
intensity projections are displayed. Bars, 10 µm. (C) Human monocyte-derived macrophages were differentiated in the presence of 10% FBS and 100 ng/ml 
M-CSF for 5 d and subsequently infected with mature virions of vaccinia virus WR E VHHASC-EGFP L mCherry or WR E VHH NP1-EGFP L mCherry at an MOI 
of 20. Cells were fixed 18 h after infection and stained for DNA. Z stacks of representative cells were recorded by spinning disc confocal microscopy and 
images of maximum intensity projections are shown. Bars, 10 µm.
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pressing the control VHH NP1-EGFP. The occurrence of 
filamentous VHHASC-EGFP structures in response to two dif-
ferent activators of ASC PYD polymerization thus confirmed 
that filamentous VHHASC-EGFP assemblies are readouts for 
ASC PYD filament formation.
VHHASC-EGFP assembles along ASC filaments in 
response to NAIP/NLRC4 triggers
Efficient cytokine maturation in response to the NAIP/
NLRC4 trigger MxiH involves multimolecular ASC com-
plexes because ASC foci accrued upon stimulation and 
VHHASC reduced IL-1β secretion. Unlike NLRP3 and 
AIM2, NLRC4 does not contain a PYD and therefore 
cannot directly nucleate the oligomerization of ASC fila-
ments by PYD–PYD interactions. Two scenarios that allow 
NLRC4 to induce the formation of ASC filaments are 
conceivable: NLRC4 may directly nucleate the formation 
of ASC filaments via the ASCCARD. Indeed, both overex-
pressed ASCCARD in cells (Masumoto et al., 2001b), as well 
as purified ASCCARD in vitro (Fig.  3 B), can oligomerize 
into filament-like structures. Alternatively, NLRC4 may 
bind one or several ASC molecules through its CARD, 
which in turn changes the conformation of the bound ASC 
molecules, so that ASC itself can nucleate the formation of 
ASC filaments using its PYD. This scenario would resem-
ble the situation observed for NLRP3 and AIM2. To test 
which of the two possibilities applies, we triggered THP-1 
VHHASC-EGFP and THP-1 VHH NP1-EGFP with cyto-
solically delivered MxiH in the presence of the caspase-1 
inhibitor z-YVAD-cmk to reduce pyroptotic cell death. 
When cells expressing VHHASC-EGFP were treated with 
MxiH, we observed filamentous EGFP structures in many 
cells (Fig. 7, D and G). The EGFP structures were similar 
to those found when NLRP3 was activated by K+ efflux 
(nigericin), or when AIM2 was activated by DNA. Fila-
mentous assemblies did not occur in the absence of inflam-
masome triggers and were never observed in cells expressing 
VHH NP1-EGFP. Based on the specificity of VHHASC for 
ASCCARD, the EGFP structures seen upon NLRP3/AIM2 
activation must be comprised of VHHASC-EGFP mole-
cules aligned along ASCPYD filaments, by binding to the 
free ASCCARD. We therefore reasoned that NAIP/NLRC4 
activation also involves the formation of ASC filaments po-
lymerized via ASCPYD. In that case, one or several initiator 
ASC molecules are presumably activated by NLRC4 and 
turned into nucleators of ASCPYD polymerization.
In summary, our data on VHHASC-EGFP filament for-
mation demonstrate that the activation of NAIP/NLRC4 
inflammasomes involves the formation of ASC filaments 
that assemble by polymerization of ASCPYD. As in the case 
of NLRP3, the ASCCARD is likely to also have a dual role 
in inflammasome activation: it mediates cross-linking of lin-
ear ASC fibers, and recruits the effector pro–caspase-1 to the 
macromolecular complex.
VHHASC-EGFP assembles along ASC filaments in vaccinia 
virus–infected human macrophages
To rule out that the observed VHHASC-EGFP assemblies along 
ASCPYD filaments constitute an artifact of the monocytic leu-
kemia cell line THP-1, we analyzed inflammasome activation 
in differentiated human macrophages derived from peripheral 
blood monocytes. To express VHHASC-EGFP in macrophages 
and at the same time activate inflammasomes, we generated 
a recombinant vaccinia virus (VACV) strain, which expresses 
VHHASC-EGFP or VHH NP1-EGFP under the control of an 
early viral promoter and mCherry under the control of a late 
viral promoter. Infection of mouse macrophages and THP-1 
cells with this DNA virus induces inflammasome activation 
in an AIM2 or NLRP3-dependent manner (Delaloye et al., 
2009; Hornung et al., 2009). Consistently, THP-1 cells in-
fected with mature virions of VACV E VHHASC-EGFP exhib-
ited filamentous EGFP-positive assemblies (unpublished data). 
Many monocyte-derived macrophages infected with VACV 
E VHHASC-EGFP contained filamentous assemblies of EGFP, 
whereas control cells infected with VACV E VHH NP1-EGFP 
did not (Fig. 8 C). We did not observe mCherry expression in 
the vast majority of cells, suggesting that virus entry or early 
gene expression is sufficient for inflammasome activation. Of 
note, most VACV-infected human monocyte–-derived mac-
rophages exhibited signs of pyroptotic or apoptotic cell death, 
including nuclear fragmentation. In conclusion, we found that 
VHHASC-EGFP assemblies along ASCPYD filaments also occur 
in primary human macrophages and therefore visualize a gen-
uine intermediate in inflammasome activation.
DIS CUS SION
Inflammasomes are critical information hubs of the innate 
immune system. A lack of appropriate tools to perturb in-
flammasomes in physiological conditions has hampered a 
more complete molecular understanding of the underlying 
cell biology and of the molecular interactions involved. We 
generated and characterized VHHASC, an alpaca single do-
main antibody that recognizes the CARD of the human 
inflammasome adapter ASC. Its introduction into the cyto-
plasm of living cells allowed us to occlude a key interaction 
interface of ASC, while leaving the function of its ASCPYD 
unperturbed. This approach proved to be more informative 
than genetic ablation of ASC altogether. The application of 
VHHs to explore events in the cytoplasm complements more 
conventional genetic approaches: without having to resort 
to deletions or point mutations, protein–protein interac-
tions can be perturbed conditionally. The ability of VHHs 
to serve as crystallization chaperones for proteins that have 
proven difficult to crystallize, too, allows identification of the 
exact molecular interfaces concerned. VHHs thus provide 
new mechanistic insights.
Using VHHASC, we demonstrated the role of ASC in 
NLRP3, AIM2, and NAIP/NLRC4-dependent IL-1β secre-
tion. VHHASC also allowed us to tease apart the functions of the 
ASC domains involved: ASCPYD forms filaments in response to 
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its direct nucleation by NLRP3PYD and AIM2PYD, or in response 
to the engagement of linker ASC molecules by NLRC4CARD 
(Fig. 9 A). ASCCARD appears critical in cross-linking the multi-
ple ASCPYD filaments formed (Fig. 9 B), which consolidates all 
ASC molecules into a single supramolecular organizing center 
(Kagan et al., 2014; Hauenstein et al., 2015), also known as ASC 
speck or focus. Moreover, we confirmed the role of ASCCARD 
in the recruitment and subsequent activation of pro–caspase-1.
Identification and characterization of VHHASC included 
solving the structure of the VHHASC alone and in complex 
with ASCCARD. We thus established that VHHASC occludes 
the type II interface of the ASCCARD. Immunoprecipita-
tion experiments demonstrate that VHHASC readily interacts 
with ASC from unstimulated cells, suggesting that coex-
pressed VHHASC likely forms stable complexes with ASC in 
cells. We further showed that the type II interface of ASC 
Figure 9. Molecular model of inflam-
masome activation. (A) Mechanism of ASC 
filament formation nucleated by NLRP3 (left) 
and NAIP/NLRC4 (right). (B) Model of ASC 
filament cross-linking mediated by ASCCARD. 
(C) Modeled structure of ASC filament covered 
with VHHASC. Relative arrangement of ASCPYD, 
ASCCARD, and VHHASC is shown. ASCCARD–VHHASC 
unlikely follows the exact helical symmetry of 
the PYD filament core as a result of the flexible 
linker between PYD and CARD. (D) Schematic 
representation of ASC focus formation in un-
perturbed conditions, and formation of ASC 
filaments coated with VHHASC-EGFP.
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is required for homotypic CARD–CARD interactions with 
other ASC molecules and pro–caspase-1, and that both in-
teractions were perturbed by VHHASC in well-defined in 
vitro polymerization assays.
Our findings—in vitro, in cell lines, and in primary 
cells—expand a model of inflammasome activation that in-
volves the local polymerization of inflammasome compo-
nents, recently put forward based on in vitro studies and 
yeast prion assays (Cai et al., 2014; Lu et al., 2014). We 
demonstrate that endogenous ASC can form ASCPYD fila-
ments at endogenous ASC levels in the relevant cell type, 
ruling out any artifacts that may be caused by overexpression 
or by a lack of regulatory factors. Once NLRP3 is activated, 
NLRP3PYD directly nucleates ASCPYD filaments by inducing 
an ASC conformation that drives polymerization. Assem-
bly of NAIP/NLRC4 inflammasomes is a more intriguing 
case: activation of NAIP/NLRC4 by bacterial needle pro-
teins yields ASCPYD filaments, as well. We therefore reasoned 
that NLRC4CARD must use linker molecules of ASC via 
its CARD. This is in line with yeast prion assays, in which 
NLRC4CARD-triggered formation of ASC–Sup35C prions 
was dependent on both oligomerization-competent PYD 
and CARD (Cai et al., 2014). In a mechanism that requires 
further structural characterization, NLRC4CARD induces 
an active conformation of ASC by binding its ASCCARD, 
which then nucleates PYD-mediated ASC filaments 
(Fig. 9 A). Mere engagement of the ASC CARD was not 
sufficient for activation, as binding of ASCCARD by VHHASC 
neither induced the formation of filaments nor led to IL-1β 
secretion. Similarly, in yeast experiments, caspase-1CARD was 
insufficient to induce polymerization of ASC–Sup35C pri-
ons (Cai et al., 2014). In light of our structural understand-
ings, the VHHASC–ASC complex would presumably retain 
its ability to interact with NLRC4. Because complex for-
mation occludes only the type IIb interface, the intact type I, 
III, and IIa interfaces would allow the VHHASC-bound ASC 
to interact with activated NLRC4 by forming a small layer 
of ASC to nucleate ASCPYD filament formation (Fig. 10).
ASC is dispensable for NAIP/NLRC4-dependent 
pyroptosis in human cells, because VHHASC does not im-
pair LDH release in response to MxiH treatment. Simi-
larly, Salmonella-induced pyroptosis of mouse macrophages 
does not require ASC, whereas it is necessary for efficient 
cytokine release (Broz et al., 2010b). Direct recruitment 
of pro–caspase-1 by NLRC4 may be sufficient to trigger 
caspase-1–dependent cell death. However, neutrophils are 
insensitive to pyroptosis when NAIP/NLRC4-dependent 
cytokine secretion was induced by Salmonella infection 
(Chen et al., 2014). The fact that pyroptosis did not occur 
in neutrophils from ASC−/− mice, despite the presence of 
Figure 10. Model of small oligomer of ASCCARD complexed by VHHASC. (A) An ASCCARD oligomer (orange) with bound VHHASC (gray) was modeled based 
on the MAVSCARD filament symmetry and the ASCCARD/VHHASC structure. VHHASC occludes type IIb interface of ASCCARD, but does not interfere with small oligo-
mer assembly. (B) A few ASC molecules bound to activated NLRC4 are sufficient to nucleate the formation of ASCPYD filaments even in the presence of VHHASC.
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activated NLRC4 and pro–caspase-1, shows that regulation 
of pyroptosis is more complex than currently understood.
By masking the type II interface of ASCCARD, but not 
ASCPYD, we stabilized an intermediate state in inflammasome 
activation (Fig. 9 C). We often observed multiple ASCPYD fila-
ments at the same time, indicating that nucleation can occur at 
multiple sites. Typically, only a single ASC focus is observed per 
cell, which suggests that several ASC filaments coalesce into a 
single microscopic structure during inflammasome assembly. 
This requires ASCCARD, which is in line with our observa-
tion that in vitro inclusion of VHHASC prevents ASC CARD–
CARD interactions and blocks the cross-linking of full-length 
ASC filaments (Fig. 9 D). We cannot rule out that ASCCARD 
might also facilitate a transport mechanism that brings mul-
tiple ASC filaments together. A coalescence step involving 
the cross-linking of multiple ASC filaments would elegantly 
explain the formation of inflammasomes involving different 
NLRs, such as the mixed NLRP3/NLRC4 inflammasomes 
observed in Salmonella-infected mouse macrophages (Man et 
al., 2014). Activation of different NLRs may trigger polymer-
ization of individual ASC filaments that later join to form a 
single ASC focus. Lastly, masking ASCCARD with VHHASC also 
prevents the recruitment of caspase-1 and therefore prevents 
the ultimate outcome of inflammasome activation, the auto-
catalytic activation of caspase-1. This work has implications for 
the development of antiinflammatory agents that could work 
by targeting the type II interaction face on ASCCARD and may 
pave the way for further perturbation studies using single do-
main antibodies as research tools.
MAT ERI ALS AND MET HODS
Primary cells. Human monocytes were isolated from human 
whole blood buffy coat obtained from VWR International. 
Cells were purified using a Ficoll-Paque Plus (GE Health-
care) cushion, and monocytes adhered to coverslips in RPMI 
for 2  h. Cells were differentiated in RPMI supplemented 
with 10% FBS and 100 ng/ml recombinant human 
M-CSF (BioLegend) for 5 d.
Cell lines. Human epithelial A549 cells were grown in DMEM 
supplemented with 10% FBS; human monocyte-like THP-1 
cells were cultivated in RPMI medium supplemented with 
10% FBS and 50 µM 2-mercaptoethanol. THP-1 cell lines in-
ducibly expressing VHHASC-HA, VHH NP-1-HA, VHHASC- 
EGFP, VHH NP-1-EGFP, and EGFP were generated 
using lentiviruses produced with derivatives of pInducer20 
(Meerbrey et al., 2011) and selected in THP-1 medium 
with 500 µg/ml geneticin.
Virus strains. Vaccinia virus strains Western Reserve (WR) E 
VHHASC-EGFP L mCherry and WR E VHH NP1-EGFP 
L mCherry express VHH-EGFP fusions under the control 
of the J2R early promoter and mCherry under the control 
of the F17R late promoter. The virus strains were derived 
from WR WT using plasmids based on pJS4 (Chakrabarti et 
al., 1997) to insert transgenes into the tk locus. Recombi-
nant viruses were identified based on mCherry expression 
and purified through three rounds of plaque purification. 
Mature virions were produced in BSC-40 cells and puri-
fied from cytoplasmic extracts through a 16% sucrose cush-
ion in 20 mM Tris, pH 9.0.
Reagents. Doxycycline hyclate was purchased from Sigma- 
Aldrich; E. coli K12 LPS, nigericin, and poly(dA:dT) were 
obtained from InvivoGen. PMA was purchased from Santa 
Cruz Biotechnology, Inc.; TAK-242 was obtained from EMD 
Millipore; and z-YVAD-cmk was purchased from Bio-
Techne. Mouse anti-HA.11 (clone 16B12) was acquired from 
BioLegend, mouse anti-EGFP (clone JL-8) was purchased 
from Takara Bio Inc., mouse anti–IL-1β (clone 3A6) was ob-
tained from Cell Signaling Technology, rabbit anti–caspase-1 
p10 (C-20) was purchased from Santa Cruz Biotechnology, 
Inc., and rabbit anti-ASC (AL177) was obtained from Adipo-
gen (all antibodies against the human homologues). 
HRP-coupled sheep anti–mouse IgG was purchased from 
GE Healthcare, HRP-coupled goat anti–rabbit IgG was ob-
tained from SouthernBiotech, HRP-coupled goat anti–llama 
IgG was obtained from Bethyl Laboratories, peroxidase- 
coupled rat anti-HA (clone 3F10) was obtained from Sigma 
Aldrich, and HRP-coupled mouse anti-GAP DH (clone 
6C5) was purchased from Abcam. Fluorescent secondary an-
tibodies were acquired from Life Technologies.
VHH library generation. To raise heavy chain-only antibodies 
against human ASC, one alpaca was immunized five times with 
a mixture of proteins, including MBP-ASC. A VHH plasmid 
library in the M13 phagemid vector pJSC was generated as 
previously described (Maass et al., 2007; Sosa et al., 2014). In 
brief, RNA from peripheral blood lymphocytes was extracted 
and used as a template to generate cDNA using three sets of 
primers (random hexamers, oligo[dT], and primers specific for 
the constant region of the alpaca heavy chain gene). VHH cod-
ing sequences were amplified by PCR using VHH-specific 
primers, cut with AscI and NotI, and ligated into pJSC linear-
ized with the same restriction enzymes. E. coli TG1 (Agilent) 
cells were electroporated with the ligation reaction and the 
obtained ampicillin-resistant colonies (∼3 × 106) harvested, 
pooled, and stored as glycerol stocks.
VHH phage display and panning. ASC-specific VHHs were 
obtained by phage display and panning with a protocol mod-
ified from a previous study (Sosa et al., 2014). E. coli TG1 
cells containing the VHH library were infected with helper 
phage VCSM13 to produce phages displaying the encoded 
VHHs as pIII fusion proteins. Phages in the supernatant were 
purified and concentrated by precipitation; phages display-
ing MBP-specific VHHs were removed in a depletion step 
with MBP immobilized to the bottom of tissue culture flasks. 
Phages presenting ASC-specific VHHs were enriched using 
biotinylated MBP-ASC immobilized to MyOne Streptavi-
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din T1 Dynabeads (Life Technologies) in the presence of ex-
cess soluble MBP and 500 mM NaCl. The obtained phages 
were used to infect E. coli ER2738 and subjected to a second 
round of panning. 96 E. coli ER2837 colonies yielded in the 
second panning were grown in 96-well plates and VHH ex-
pression was induced with IPTG. VHHs leaked into the su-
pernatant were tested for specificity using ELI SA plates coated 
with MBP or MBP-ASC; bound VHHs were detected with 
HRP-coupled rabbit anti–E-Tag antibodies (Bethyl Lab-
oratories) and the chromogenic substrate TMB. The amino 
acid sequence of VHHASC is: QLQ LVE SGGG LVQ PGG 
SLKL SCA ASG FTFS RYA MSW YRQA PGK ERE SVAR 
ISS GGG TIYY ADS VKG RFTI SRE DAK NTVY LQM NSL 
KPED TAV YYC YVGG FWG QGT QVTV SS.
Protein expression and purification. For periplasmic bacterial 
expression, VHH coding sequences were cloned into a deriva-
tive of pHEN6 (Conrath et al., 2001) encoding a C-terminal 
sortase recognition site (LPE TG), followed by a His6-tag. 
VHHASC-LPE TG-His6 and VHHEnhancer-LPE TG-His6 were 
expressed in E. coli WK6 cells and purified from periplasmic 
extracts using Ni-NTA affinity purification and size-exclusion 
chromatography with a HiLoad 16/600 Superdex 75 pg col-
umn. To fluorescently label VHHs using sortase, proteins were 
incubated with sortase and GGG-Alexa Fluor 647, as previ-
ously described (Guimaraes et al., 2013), followed by removal 
of His-tagged sortase and size-exclusion chromatography.
For cytoplasmic expression, VHHASC was cloned into 
pETDuet-1, expressed in E. coli BL21(DE3), and purified 
by Ni-NTA purification and size-exclusion chromatogra-
phy with a Superdex 200 10/300 GL column. ASCCARD 
(N128A/E130R) was expressed using a pET28a-based vec-
tor in E. coli BL21(DE3) and purified as described for the 
cytoplasmic expression of VHHASC.
For fluorescence polarization assay, MBP-ASCCARD- 
SUMO and MBP-ASC-caspase-1CARD-SUMO constructs 
were expressed and purified as described in our previous 
study (Lu et al., 2014). In short, ASCCARD (107–195) or 
caspase-1 (1–95) was cloned into modified pDB-His-MBP 
vector containing the sequence of SUMO C-terminal to the 
inserted gene. For GFP-ASCCARD expression, pET28a was 
modified to obtain an N-terminal GFP (monomeric) fu-
sion protein, followed by insertion of ASCCARD in frame to 
GFP. The MBP-ASCFL was described previously (Lu et al., 
2014). The Y187A mutation on MBP-ASC was introduced 
by QuikChange site-directed mutagenesis (Agilent Technol-
ogies). All proteins were expressed in BL21(DE3) cells and 
purified by Ni-NTA affinity chromatography, followed by 
size-exclusion chromatography.
For expression of Bacillus anthracis PA, E. coli BL21(DE3) 
cells were transformed with pGEX-6P-1 PA. GST-PA was 
expressed and bound to glutathione-S agarose, followed by 
release of PA with PreScission protease (GE Healthcare), as 
previously described (Wu et al., 2010). PA was further pu-
rified by anion exchange chromatography with a Mono 
Q column. His6-LFn-MxiH WT and His6-LFn-MxiH 2A 
(containing point mutations V58A and I78A) were expressed 
in E. coli BL21(DE3) using vectors derived from pET-15b 
LFN-DTA, a gift from J. Collier (Harvard Medical School, 
Boston, MA)(Addgene plasmid #11075; Milne et al., 1995), 
and purified by Ni-NTA affinity purification and size-exclu-
sion chromatography with a HiLoad 16/600 Superdex 75 pg 
column. Endotoxins were removed from PA and LFn-MxiH 
preparations using two extractions with Triton X-114, fol-
lowed by removal of remaining detergent with Bio-Beads 
SM-2 beads (Bio-Rad Laboratories; Aida and Pabst, 1990).
X-ray crystallography. VHHASC crystals grew in a condition 
containing 0.1 M citric acid, pH 3.5, and 35% PEG3350. 5 µl 
of sample at ∼15 mg/ml was mixed with 5 µl of the reservoir 
condition in a 24-well sitting drop tray (Hampton Research). 
Crystals appeared during overnight incubation. Crystals were 
recovered and washed in reservoir condition supplemented 
with 25% glycerol. The dataset was collected at the APS 24-
ID-C beamline at 0.979 Å.
For structure determination, molecular replacement was 
used for phase determination with a predicted model from 
SWI SS-MOD EL (based on a VHH structure deposited in 
RCSB PDB under code: 3UX9). Manual structure refine-
ment was done using the COOT program (Emsley and Cow-
tan, 2004), and iterative automatic refinement was performed 
in PHE NIX (Adams et al., 2010). Ramachandran plots indi-
cate 96.4% (3.6%) in the favored (allowed) region.
VHHASC–ASCCARD (N128A/E130R) complex crystals 
were grown in a condition containing 0.1 M citric acid at pH 
3.5 and 3 M sodium chloride. Ni-NTA–purified ASCCARD 
(N128A/E130R) was mixed and concentrated with over-stoi-
chiometric amounts of Ni-NTA-purified VHHASC. Excess 
VHH was removed from the complex by size-exclusion 
chromatography on a Superdex 75 column. The complex 
sample was concentrated to >30 mg/ml and mixed 1 µl:1 µl 
with reservoir condition in a hanging-drop vapor diffusion 
experiment. Needle clusters appeared after 4 d of incubation. 
Crystals were separated into individual needles and frozen 
in reservoir condition supplemented with 25% glycerol. The 
dataset was collected at the APS 24-ID-C beamline at 0.979 
Å. Phase determination was performed in Phaser using nano-
body crystal structure and the NMR structure of ASCCARD 
(RCSB PDB code: 2KN6; de Alba, 2009) as search models. 
Both structures were first trimmed to poly-alanine sequence 
using the Chainsaw in CCP4. Subsequent refinements were 
performed in PHE NIX using the ASC and VHHASC struc-
tures as reference models to provide restrains. Manual model 
adjustment, including replacement of residues at interface, 
was done in COOT. Ramachandran plots indicate 96% (4%) 
in the favored (allowed) region.
The structures of VHHASC and the complex VHHASC– 
ASCCARD (N128A/E130R) have been deposited in the 
RCSB Protein Data Bank (PDB) with the accession codes 
5H8D and 5H8O.
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Immunoprecipitation. For the immunoprecipitation of en-
dogenous ASC, 4 mg VHHASC and VHHEnhancer were cova-
lently coupled to 0.25  g CNBr-activated Sepharose 6B 
(Sigma-Aldrich). 8 × 107 THP-1 EGFP cells (grown in the 
presence of 1 µg/ml doxycycline for 24 h to induce EGFP 
expression) were lysed in a high-salt lysis buffer (50 mM Tris, 
pH 7.4, 500 mM NaCl, and 1% NP-40, and protease inhibi-
tor cocktail [Roche]), and lysates were bound to the VHH 
beads in the cold. After extensive washes, bound proteins were 
eluted with 0.2  M glycine pH 2.0 and analyzed by SDS-
PAGE. The major bands were cut out of the gel and the con-
tained proteins identified by mass spectrometry.
LUM IER assay. Protein interactions in transfected A549 cells 
were quantified using the LUM IER assay according to a 
protocol modified from Taipale et al. (2012). A549 cells in 
24-well trays were transfected with 0.5 µg bait expression 
vectors (pCAG GS VHHASC-HA or pCAG GS VHH 
NP1-HA), and 0.5 µg prey expression vectors (empty vec-
tor, pEXPR hASC-Renilla, pEXPR hASCCARD-Renilla, 
pEXPR hASCPYD-Renilla, or pEXPR mASC-Renilla, all 
derived from pcDNA3-ccdB-Renilla; a gift from M. Taipale 
and S. Lindquist, Whitehead Institute, Cambridge, MA) 
using Lipofectamine LTX (Life Technologies). 2 d after 
transfection, cells were lysed in 120 µl LUM IER IP buffer 
(50 mM Hepes, pH 7.9, 150 mM NaCl, 2 mM EDTA, pH 
8.0, 0.5% Triton X-100, 5% glycerol, and protease inhibitor 
cocktail [Roche]). 90 µl of the lysates were transferred to 
blocked LUM ITR AC 600 plates (Greiner) coated with 
mouse anti-HA.11 and incubated at 4°C for 3 h. After ex-
tensive washing steps with IP buffer, incubated wells 
(or 10  µl lysate) were incubated with Coelenterazine- 
containing Renilla luciferase substrate mix (BioLux Gaussia 
Luciferase Assay kit; New England BioLabs) and light emis-
sion was quantified using a SpectraMax M3 microplate 
reader (Molecular Devices). Renilla luciferase activity in the 
immunoprecipitation samples was normalized by Renilla 
luciferase activity in the lysates.
Fluorescence polarization assays. The detailed protocol for 
fluorescence polarization assays is described in our previous 
study (Lu et al., 2014). In short, MBP-ASCCARD-SUMO and 
MBP-caspase-1CARD-SUMO containing a C-terminal sortase 
motif were fluorescently labeled as previously described 
(Guimaraes et al., 2013). Monomeric proteins were incubated 
with TEV protease to remove the MBP fusion. The rate of 
polymerization was enhanced by addition of the oligomeric 
GFP-ASCCARD. To assay for inhibitory effect, VHHASC was 
added to the mixture before MBP removal.
NLRP3 activation assays. To assay NLRP3 inflammasome ac-
tivation, THP-1 cell lines were differentiated in the presence 
of 50 ng/ml PMA for 16 h, followed by incubation in THP-1 
medium with or without 1 µg/ml doxycycline for 24 h. Cells 
were then incubated with 200 ng/ml LPS in THP-1 medium 
for 3 h, followed by treatment with 5 µM nigericin in Opti-
MEM for 45 min, both in the absence of doxycycline. Super-
natants were cleared by centrifugation (1,000 g, 4°C, 10 min) 
and analyzed by ELI SA or immunoblot.
AIM2 activation assays. To assay AIM2 inflammasome activa-
tion, THP-1 cells were differentiated and gene expression was 
induced as described for NLRP3 activation assays. Cells were 
incubated with 200 ng/ml LPS in THP-1 medium for 3 h, 
followed by transfection of 1 µg/ml poly (dA:dT) with 
1.75  µl/ml Lipofectamine 2000 (final concentrations on 
transfected cells indicated). Supernatants were harvested and 
cleared after 4 h as described for NLRP3 activation assays.
NAIP/NLRC4 activation assays. To assay NAIP/NLRC4 in-
flammasome activation, THP-1 cell lines were differentiated 
and gene expression induced as described for NLRP3 acti-
vation assays. Cells were incubated with 1 µg/ml PA and 
0.1 µg/ml LFn-MxiH WT or 2A in THP-1 medium sup-
plemented with 20  µM of the TLR4 inhibitor TAK-242. 
After 3  h, supernatants were harvested and cleared as de-
scribed for NLRP3 activation assays.
Vaccinia virus infection assays. To infect cells with vaccinia 
virus, mature virions were diluted in DMEM and used to 
infect cells at a multiplicity of infection (MOI) of 20. 30 min 
after infection, the inoculum was removed and cells were cul-
tivated in full medium for 17.5 h.
IL-1β and TNF ELI SAs. Concentrations of mature IL-1β and 
TNF in cell culture supernatants were quantified using the 
OptEIA Human IL-1β ELI SA Set II or the OptEIA Human 
TNF ELI SA Set (both BD) according to the manufacturer’s 
instructions. Typically, 2 × 105 cells were covered with 0.5 ml 
medium and 1:100 dilutions of the cleared supernatants were 
used for the ELI SA. Statistical significance of differences was 
evaluated using the Student’s t test.
LDH activity assay. Lactate dehydrogenase activity in cell cul-
ture supernatants was quantified using the LDH Cytotoxicity 
Detection kit (Takara Bio Inc.). Typically, 1:2 dilutions of 
cleared supernatants (see IL-1β ELI SA) were used for the 
assay according to the manufacturer’s instructions. LDH ac-
tivity was corrected by the background LDH activity in the 
medium and normalized to the LDF activity of a well of cells 
lysed with 1% Triton X-100.
Immunoblots. To analyze secretion and maturation of 
caspase-1 and IL-1β by immunoblot, cleared supernatants 
from 2 × 106 THP-1 cells (covered with 1 ml Opti-MEM) 
were concentrated by methanol/chloroform precipitation, as 
described by Jakobs et al. (2013). Proteins were separated by 
SDS-PAGE and transferred to PVDF membranes. IL-1β was 
detected with mouse anti–IL-1β (clone 3A6, 1:1,000 in 5% 
BSA/TBS-T) and HRP-coupled sheep anti–mouse IgG; 
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caspase-1 was detected with rabbit anti-caspase-1 p10 (1:200 
in 5% milk/TBS-T) and HRP-coupled goat anti–rabbit IgG.
Immunofluorescence microscopy. To stain proteins for im-
munofluorescence microscopy, cells were fixed with 4% 
formaldehyde and permeabilized in permeabilization 
buffer (PS; 0.05% saponin, 1% BSA, and 0.05% NaN3 in 
PBS) for 20 min. Samples were incubated with rabbit anti- 
ASC (1:200 in PS) for 2 h, washed with PBS, and subse-
quently incubated with Alexa Fluor 594–coupled goat anti–
rabbit IgG (1:1,000), Hoechst 33342 (1:5,000), and, where 
indicated, with Alexa Fluor 647–coupled VHHASC or VHH 
NP1 (1 µg/ml) for 1 h. Samples were washed with PBS and 
H2O, and mounted with Fluoromount-G (Southern Bio-
tech) or Duolink In Situ Mounting Medium with DAPI 
(Sigma-Aldrich). Images were acquired using a PerkinElmer 
Ultraview Spinning Disk Confocal microscope or a Nikon 
Eclipse Ti wide field microscope. ASC foci and nuclei in 
wide field microscopy images were quantified using the spot 
detection function of the Imaris software package (Bitplane).
Online supplemental material. Tables S1 and S2 show 
crystallographic information. Online supplemental 
material is available at http ://www .jem .org /cgi /content 
/full /jem .20151790 /DC1.
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